GH Research PLC is a clinical stage biopharmaceutical company focused on developing novel mebufotenin based therapies for psychiatric and neurological disorders. The company's lead product candidate GH001 is an inhalable formulation of mebufotenin being studied for treatment resistant depression. A second candidate GH002 is an intravenous formulation intended for use when inhalation may not be feasible. GH Research PLC aims to deliver therapies that act quickly have a durable effect and are convenient for patients. The firm's approach targets rapid receptor activation to modulate serotonergic signaling and induce antidepressant effects. To date the company has completed multiple phase one and phase two trials in healthy volunteers and patients with depression demonstrating safety and preliminary efficacy.

As a company still in the clinical development stage GH Research PLC does not generate revenue from product sales. Its current activities are limited to research and development and it relies on external financing to fund its programs. The company has raised capital through public offerings and private placements to support its research efforts. Management anticipates that future revenue will arise from product sales after obtaining regulatory approval and launching the therapies in target markets.

GH Research PLC operates in a competitive landscape that includes approved therapies for treatment resistant depression such as esketamine sold as Spravato and the olanzapine fluoxetine combination. Other companies developing novel treatments include AtaiBeckley Axsome Therapeutics COMPASS Pathways Helus Pharma and Definium Therapeutics. The firm believes its approach offers a rapid onset of effect and a convenient dosing regimen that could differentiate it from existing options. Its intellectual property portfolio includes numerous patent families covering various formulations delivery methods and uses which may provide a barrier to entry. The company also notes that its product candidates are designed to be administered without requiring additional psychotherapy visits which may improve patient adherence. Market research suggests there are approximately nine million treatment resistant patients in the United States and Europe representing a significant unmet need. GH Research PLC expects its therapies to reduce the health care burden associated with long treatment courses and frequent visits.

The company intends to sell its products to health care providers including hospitals psychiatric clinics and specialty treatment centers in the United States and Europe. It also plans to engage with private insurers and public payers to obtain coverage and reimbursement. GH Research PLC works with contract development and manufacturing organizations to produce active pharmaceutical ingredient and final drug product. No specific customer names have been disclosed in the filing.